FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
22014019340707/10/14Drug fusions and conjugates
32014018775007/03/14Methods for selecting protease resistant polypeptides
42014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
52014015870406/12/14Medicament dispenser
62014014099605/22/14Anti-serum albumin biding variable domains
72014014099605/22/14Anti-serum albumin biding variable domains
82014011643405/01/14Dry powder inhaler compositions
92014011643405/01/14Dry powder inhaler compositions
102014011292904/24/14Tumour necrosis factor receptor 1 antagonists
112014011388804/24/14Novel combination of therapeutic agents
122014011392204/24/14Compounds
132014011292904/24/14Tumour necrosis factor receptor 1 antagonists
142014011388804/24/14Novel combination of therapeutic agents
152014011392204/24/14Compounds
162014010589404/17/14Humanized anti-il-18 antibodies
172014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
182014010589404/17/14Humanized anti-il-18 antibodies
192014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
202014007631403/20/14Manifold for use in medicament dispenser
212014008086303/20/14Muscarinic acetylcholine receptor antagonists
222014007631403/20/14Manifold for use in medicament dispenser
232014008086303/20/14Muscarinic acetylcholine receptor antagonists
242014005690002/27/14Method for inhibiting binding to b-cell receptor
252014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
262014005071902/20/14Antibodies
272014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
282014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
292014002359601/23/14Novel composition
302014002455801/23/14Method of treatment
312014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
322014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
332013034546512/26/13Process for the preparation of retigabine
342013033698912/19/13Methods of identifying a patient population
352013031590111/28/13Novel uses
362013031704111/28/13Compounds
372013031028111/21/13Novel antigen binding proteins
382013030233511/14/13Ligands that bind tgf-beta receptor ii
392013026771710/10/13Process for the preparation of atovaquone
402013026118510/03/13Benzamide derivatives as ep4 receptor agonists
412013025172409/26/13Antigen binding proteins to oncostatin m (osm)
422013025318809/26/13Novel compounds
432013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
442013022420408/29/13Method of treatment based on atad2 inhibitors
452013022420408/29/13Method of treatment based on atad2 inhibitors
462013021315408/22/13Method of determining cleanliness
472013021339408/22/13Dispensing device
482013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
492013021315408/22/13Method of determining cleanliness
502013021339408/22/13Dispensing device
512013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
522013021089208/15/13Method of treatment
532013021089208/15/13Method of treatment
542013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
552013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
562013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
572013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
582013019641208/01/13Magi polynucleotides, polypetides, and antibodies
592013019641208/01/13Magi polynucleotides, polypetides, and antibodies
602013018925507/25/13Fusions and conjugates of insulinotropic agents
612013018925507/25/13Fusions and conjugates of insulinotropic agents
622013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
632013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
642013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
652013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
662013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
672013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
682013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
692013007819803/28/13Novel use
702013005337502/28/13Amino-quinolines as kinase inhibitors
712013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
722013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
732013003001201/31/13Compounds
742013003001501/31/13Muscarinic acetylcholine receptor antagonists
752013002354101/24/13Voltage-gated sodium channel blockers
762013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
772012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
782012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
792012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
802012028854411/15/12Novel retigabine composition
812012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
822012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
832012024074209/27/12Novel device
842012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
852012023855909/20/12Novel compounds
862012023857109/20/12Indazole derivatives as pi 3-kinase
872012023206109/13/12Novel compounds
882012020774908/16/12Dosing regimen
892012020281108/09/12Novel compounds
902012015744606/21/12Medical use
912012015749106/21/12Muscarinic acetylcholine receptor antagonists
922012015749206/21/12Antibiotic drug
932012014971106/14/12Piperidine derivatives used as orexin antagonists
942012014973106/14/12New medical use
952012012868905/24/12Anti-il-23 immunoglobulins
962012012977805/24/12Ligand that bind tgf-beta receptor rii
972012011464705/10/12 anti-serum album single variable domains
982012010013704/26/12Immunoglobulins
992012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
1002012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1012012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1022012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1032012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1042012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1052012005896303/08/12Macrolides with anti-inflammatory activity
1062012004625802/23/12Novel crystalline pharmaceutical product
1072012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1082012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1092012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1102012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1112012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1122012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1132012000632201/12/12Drug dispenser
1142012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1152011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1162011030569212/15/11Antigen-binding contructs
1172011030569312/15/11Anitigen-binding constructs
1182011028809811/24/11Novel compounds
1192011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1202011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1212011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1222011026973811/03/11Compounds
1232011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1242011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1252011025375210/20/11Nozzle for a nasal inhaler
1262011025607410/20/11Novel use
1272011024547010/06/11Immunoglobulins
1282011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1292011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1302011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1312011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1322011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1332011015226206/23/11Novel compounds
1342011014282406/16/11Antibodies against amyloid-beta peptide
1352011014415106/16/11Novel process, salts, composition and use
1362011013569506/09/11Oral dosage form for controlled drug release
1372011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1382011011719005/19/11Pharmaceutical formulations
1392011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1402011006164603/17/11Drug dispenser
1412011006474003/17/11Antigen binding proteins
1422011006572503/17/11Triazole amide derivatives for use in therapy
1432011005916703/10/11Encapsulation of biologically active agents
1442011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1452011004502702/24/11Adjuvant
1462011004613702/24/11Pyrazole derivatives as p2x7 modulators
1472011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1482011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1492011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1502011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1512010032999612/30/10Novel combination of therapeutic agents
1522010032402212/23/10Novel compounds
1532010031657912/16/10Novel use of alkyl phosphate esters
1542010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1552010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1562010030808212/09/10Dispensing device
1572010031170612/09/10Method of treatment of allergic rhinitis
1582010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1592010030382112/02/10Immunoglobulins
1602010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1612010030512712/02/10Novel compounds
1622010030516612/02/10Novel compounds
1632010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1642010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1652010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1662010027590911/04/10Actuator for an inhaler
1672010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1682010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1692010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1702010025619910/07/10Crystalline form of an antimalarial compound
1712010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1722010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1732010022418509/09/10Actuator for an inhaler
1742010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1752010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1762010021683708/26/10Glycine transport inhibitors
1772010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1782010020325608/12/10Method and apparatus for the application of powder material to substrates
1792010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1802010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1812010019767908/05/10Compounds
1822010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1832010019076407/29/10Novel compounds
1842010018477007/22/10Compounds
1852010018499607/22/10Process of amide formation
1862010017569807/15/10Capsule
1872010017406507/08/10Compounds
1882010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1892010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1902010014401606/10/10Apparatus for the disruption of animal cells
1912010014475506/10/10Novel compounds
1922010014482906/10/10Novel receptor antagonists and their methods of use
1932010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1942010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1952010013735306/03/10Tricyclic compounds as antibacterials
1962010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1972010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1982010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1992010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2002010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2012010011379605/06/10Indole derivatives as s1p1 receptor
2022010010565204/29/10Purines as cysteine protease inhibitors
2032010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2042010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2052010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2062010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2072010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2082010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2092010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2102010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2112010006816603/18/10Oral composition comprising dimethicone copolyol
2122010006940903/18/10"novel compounds"
2132010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2142010005905203/11/10Sheet driver for use in a drug dispenser
2152010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2162010005650203/04/10Compounds
2172010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2182010005659503/04/10Pyrazole derivatives as p2x7 modulators
2192010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2202010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2212010002969902/04/10Matrix metalloproteinase inhibitors
2222010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2232010001637101/21/10Indole compounds
2242010001002101/14/10Novel compounds
2252010000052801/07/10Manifold for use in medicament dispenser
2262010000052901/07/10Manifold for use in medicament dispenser
2272010000342001/07/10Medicament dispenser
2282010000423001/07/10Azatricyclic compounds and their use
2292010000424001/07/10Indole compounds
2302009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2312009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2322009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2332009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2342009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2352009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2362009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2372009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2382009029874212/03/09Process for manufacturing lactose
2392009029114611/26/09Process for manufacturing lactose
2402009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2412009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2422009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2432009027035510/29/09Compounds
2442009027051010/29/09Glycine transport inhibitors
2452009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2462009023644509/24/09Fluid dispenser
2472009023984609/24/09Novel compounds
2482009023284709/17/09Immunogenic compositions
2492009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo